Information

Car rental manager fined after unlawfully obtaining customer data

Retrieved on: 
Wednesday, May 22, 2024

A former Management Trainee at Enterprise Rent-A-Car UK Limited ("Enterprise Rent-A-Car") has been ordered to pay a fine after admitting he illegally obtained customer data between 18 March 2019 and 1 April 2019.

Key Points: 
  • An internal audit found he’d spent 32 minutes accessing 39 records of customer data in relation to 25 different rental branches.
  • Following this, Enterprise Rent-A-Car conducted an internal investigation which found Saleem had accessed a number of records containing personal data during the offending period in 2019.
  • Saleem appeared at Huddersfield Magistrates’ Court on Monday 13 May where he pleaded guilty to unlawfully obtaining data contrary to section 170 DPA 2018.
  • Those looking for more information can also visit our website.”
    Notes to editors
    - No additional evidence was found to show Mr Saleem had sold the data or made any financial gain; therefore, the charge is for unlawfully obtaining the data.

We warn organisations must not ignore data protection risks as we conclude Snap ‘My AI’ chatbot investigation

Retrieved on: 
Wednesday, May 22, 2024

ICO concludes investigation into Snap’s approach to assessing the data protection risks of its ‘My AI’ chatbot

Key Points: 
  • In June 2023, we opened an investigation into ‘My AI’ following concerns that Snap had not met its legal obligation to adequately assess the data protection risks posed by the new chatbot.
  • The investigation led to us issuing a Preliminary Enforcement Notice to Snap on 6 October 2023.
  • We are satisfied that Snap has now undertaken a risk assessment relating to ‘My AI’ that is compliant with data protection law.
  • Organisations developing or using generative AI must consider data protection from the outset, including rigorously assessing and mitigating risks to people’s rights and freedoms before bringing products to market.

Nelnet Reports First Quarter 2024 Results

Retrieved on: 
Thursday, May 9, 2024

"We are extremely pleased with the results of the first quarter," said Jeff Noordhoek, chief executive officer of Nelnet.

Key Points: 
  • "We are extremely pleased with the results of the first quarter," said Jeff Noordhoek, chief executive officer of Nelnet.
  • AGM recognized a provision for loan losses in the first quarter of 2024 of $6.6 million ($5.0 million after tax), compared with $31.9 million ($24.2 million after tax) in the first quarter of 2023.
  • AGM acquired $80.7 million in loans in the first quarter of 2024, compared with $253.7 million for the same period in 2023.
  • As of March 31, 2024, Nelnet Bank had a $483.7 million loan portfolio and total deposits, including intercompany deposits, of $960.6 million.

Time for change: Breast screening programs must start at age 40

Retrieved on: 
Thursday, May 9, 2024

OTTAWA, ON, May 9, 2024 /CNW/ - The Canadian Cancer Society (CCS) is urging provinces and territories to lower the start age for breast screening programs to 40 for individuals at an average risk of developing breast cancer.

Key Points: 
  • OTTAWA, ON, May 9, 2024 /CNW/ - The Canadian Cancer Society (CCS) is urging provinces and territories to lower the start age for breast screening programs to 40 for individuals at an average risk of developing breast cancer.
  • Access to breast screening is important to find breast cancers early when chances of successful treatment are better.
  • While the CTFPHC is expected to release new breast screening guidelines later this month for consultation, it is provincial and territorial governments that set their respective breast screening program's start and stop ages.
  • There are a growing number of provinces across Canada who already provide access to breast screening services starting at age 40.

Solventum Reports First Quarter 2024 Financial Results and Capital Allocation Update

Retrieved on: 
Thursday, May 9, 2024

Solventum now expects an unfavorable impact from foreign exchange of ~50bps on reported sales for the full year 2024.

Key Points: 
  • Solventum now expects an unfavorable impact from foreign exchange of ~50bps on reported sales for the full year 2024.
  • 3M supply agreement mark-up started on April 1, 2024, and Solventum anticipates impact to the income statement to begin largely in the second half of 2024.
  • Solventum's full-year 2024 guidance is based on Q1 2024 3M carve-out financial information and expected results for the remainder of the year as a stand-alone company, starting April 1, 2024.
  • The Q1 2024 financial statements and financial information, including reconciliations of non-GAAP financial measures and certain prior period reconciliations, are available on Solventum's website: https://investors.solventum.com .

EQS-News: ADTRAN Holdings, Inc. reports first quarter 2024 financial results

Retrieved on: 
Friday, May 10, 2024

— May 06, 2024 — ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) (“ADTRAN Holdings” or the “Company”) today announced its unaudited financial results for the first quarter of 2024.

Key Points: 
  • — May 06, 2024 — ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) (“ADTRAN Holdings” or the “Company”) today announced its unaudited financial results for the first quarter of 2024.
  • GAAP net loss attributable to the Company for the first quarter of 2024, including the above mentioned impairment charge, was $324.6 million.
  • Non-GAAP net loss attributable to the Company for the first quarter of 2024 was $1.7 million.
  • ADTRAN Holdings’ Chairman and Chief Executive Officer Tom Stanton stated, "First quarter revenue and profitability came in as expected, with the weakness still impacting our results.

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

Retrieved on: 
Thursday, May 9, 2024

NEW YORK and WALTHAM, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the first quarter ending March 31, 2024, and provided an update on recent business achievements.

Key Points: 
  • “The first quarter of 2024 was highlighted by the initiation of our Phase 2 MaGic trial of DNTH103 for patients with gMG.
  • Initial top-line results from this trial are anticipated to be available in the second half of 2025.
  • Dianthus successfully completed a private investment in public equity (“PIPE”) financing in January 2024 that resulted in gross proceeds of approximately $230 million.
  • Additional Information - For additional information on the Company’s financial results for the quarter ended March 31, 2024, please refer to the Form 10-Q filed with the SEC.

Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

Retrieved on: 
Thursday, May 9, 2024

SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported first quarter 2024 financial results and corporate updates. 

Key Points: 
  • Launch Following U.S. Food and Drug Administration (FDA) Approval
    SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported first quarter 2024 financial results and corporate updates.
  • Iovance remains on track to onboard approximately 50 ATCs by the end of May 2024 and expects to have more than 70 ATCs onboarded by the end of 2024.
  • In the first quarter of 2024, Iovance completed the transfer of marketing authorizations and began distribution of Proleukin.
  • Beginning in the second quarter of 2024, Iovance expects to recognize significant incremental revenues for Proleukin as part of the Amtagvi treatment regimen.

Kandji Joins AWS ISV Accelerate Program to Bring Streamlined IT Resource Management to AWS Customers

Retrieved on: 
Thursday, May 9, 2024

The program helps partners drive new business and accelerate sales cycles by connecting the participating ISVs with the AWS Sales organization.

Key Points: 
  • The program helps partners drive new business and accelerate sales cycles by connecting the participating ISVs with the AWS Sales organization.
  • Through the AWS ISV Accelerate Program, Kandji receives focused co-selling support from AWS, access to further sales enablement resources, reduced AWS Marketplace listing fees, and incentives for AWS Sales teams.
  • “By joining the AWS ISV Accelerate Program, Kandji can help more customers manage and secure Apple devices in the enterprise and at scale,” said Dustin Thompson, Global VP of Partnerships at Kandji.
  • Kandji also recently passed the AWS Foundational Technical Review , which means the company aligns with AWS Well-Architected Framework .

Fossil Group, Inc. Reports First Quarter 2024 Financial Results

Retrieved on: 
Wednesday, May 8, 2024

RICHARDSON, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Fossil Group, Inc. (NASDAQ: FOSL) today announced financial results for the first quarter ended March 30, 2024.

Key Points: 
  • RICHARDSON, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Fossil Group, Inc. (NASDAQ: FOSL) today announced financial results for the first quarter ended March 30, 2024.
  • As a percentage of net sales, operating expenses were 63.8% in the first quarter of 2024 compared to 60.9% in the prior year first quarter.
  • Operating margin of (11.5)% in the first quarter of 2024 was flat with the prior year first quarter.
  • Adjusted operating margin was (7.5)% in the first quarter of 2024 compared to (7.7)% in the prior year first quarter.